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ABSTRACT
Evidence of a link between Alzheimer’s disease (AD) and
glaucoma has emerged from studies showing that
patients with AD may have a significantly increased rate
of glaucoma occurrence. In addition, it has been reported
that patients with AD exhibit optic nerve degeneration
and loss of retinal ganglion cells. In spite of intensive
research, the clinical and genetic relationships between
AD and glaucoma remain obscure. It is unclear whether
the clinical correlation between the two diseases might
be due to shared risk factors or the influence of one
disorder on the other. Interestingly, certain observations
may provide a clue towards a better understanding of the
high rate of comorbidity reported between AD and
glaucoma. In this article, we hypothesise that there may
be a causal relationship between AD and glaucoma that
may be explained by decreased cerebrospinal fluid
pressure (CSFP) in patients with AD. A very recent study
reported the intriguing new observation that mean CSFP
was 33% lower in subjects with primary open-angle
glaucoma than that of non-glaucomatous controls. It was
noted that this observation supports the concept that an
abnormal high trans-lamina cribrosa pressure difference,
whether the result of elevated intraocular pressure,
reduced CSFP, or both, plays an important role in
glaucomatous optic nerve damage. Interestingly, it was
also reported that a substantial proportion of AD patients
have very low CSFP. Therefore, we hypothesise that an
abnormal high trans-lamina cribrosa pressure difference
may explain why patients with AD have a greater risk for
developing glaucoma.
Alzheimer’s disease (AD) is a progressive neurode-
generative disorder characterised by cognitive and
memory deterioration, as well as changes in
personality, behavioural disturbances and an
impaired ability to perform activities of daily
living.1 AD is known to be the most common
form of dementia and is a major public health
problem throughout the world.2 3 In addition to
synaptic degradation and extensive neuronal cell
loss, neuropathological characteristics of AD
include extracellular senile plaques containing b-
amyloid (Ab) derived from b-amyloid precursor
protein (APP) after sequential cleavage by b-
secretase and c-secretase, and intracellular neurofi-
brillary tangles caused by abnormally phosphory-
lated tau protein.4–6 Early-onset familial AD caused
by mutations in genes encoding APP, presenilin-1
and presenilin-2 accounts for less than 5% of the
total number of AD cases.2 The majority of AD
cases are sporadic with late onset and seem to
result from a complex interaction of multiple
genetic and environmental factors.2 An important
genetic risk factor for late-onset AD is the e4 allele
of the apolipoprotein E (APOE) gene located on
chromosome 19.7 8 The pathogenesis of AD is
complex, and involves many molecular, cellular
and physiological pathologies.9 Ab is widely
believed to be central to the pathogenesis in AD.9
Glaucoma is one of the leading causes of vision
loss worldwide.8 Open-angle glaucoma (OAG), the
most common form of glaucoma, is characterised
by a progressive loss of retinal ganglion cells
(RGCs) and atrophy of the optic nerve, resulting
in loss of visual field.8 10 Mechanical and vascular
theories for the pathogenesis of glaucomatous
optic neuropathy have been proposed.10 Elevated
intraocular pressure (IOP) is a strong risk factor,
but a subset of glaucoma patients has normal IOP
and is designated normal tension glaucoma.8 10
Clearly, factors other than IOP, including genetic
factors, are likely to be involved in RGC death in
glaucoma.11 Some studies have implicated the e4
allele of the APOE gene in the pathophysiology of
OAG, but the data are conflicting.8 12 13
There is a growing body of evidence demonstrat-
ing a link between AD and glaucoma. However,
the nature of this link remains obscure.
Interestingly, recently published research may
provide a clue towards a better understanding of
the high rate of comorbidity reported between AD
and glaucoma. In this article, we hypothesise that
there may be a causal relationship between AD and
glaucoma that may be explained by decreased
cerebrospinal fluid pressure (CSFP) in patients with
AD. Supportive evidence for this hypothesis is
reviewed based on a PubMed literature search for
the period 1986 to July 2008. The search keywords,
used in different combinations, were ‘‘Alzheimer’s
disease’’, ‘‘Glaucoma’’ and ‘‘Cerebrospinal fluid
pressure’’. Fifteen articles were selected. In addi-
tion, other relevant articles were identified from
supplemental searches.
SIMILARITIES BETWEEN AD AND GLAUCOMA
It is intriguing to note that AD and glaucoma have
many common features.8 Both are slow and
chronic neurodegenerative disorders with a strong
age-related incidence.14 15 Studies consistently
report decreased levels of b-amyloid (1–42) and
increased levels of tau in cerebrospinal fluid (CSF)
from AD patients in comparison with healthy
subjects.16 17 Recently, Yoneda et al17 suggested the
possibility of a role for b-amyloid (1–42) and tau in
the pathogenesis of glaucoma and diabetic retino-
pathy, having found significantly decreased levels
of b-amyloid (1–42) and significantly increased
levels of tau in the vitreous fluid from patients
with these disorders in comparison with the levels
in a control group. Their findings suggested that
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the neurodegeneration processes in these ocular diseases might
share, at least in part, a common mechanism with AD.17 It was
also demonstrated recently that abnormal tau AT8 is present in
human glaucomas with uncontrolled elevated IOP.18
Furthermore, there is evidence of a build-up of Ab in RGCs in
experimental rat glaucoma.19 Activation of caspases and
abnormal APP processing, which includes production of Ab,
are important events in AD.19 McKinnon and colleagues19
detected a similar situation in experimental glaucoma. Indeed,
in their study using a chronic ocular hypertensive rat glaucoma
model, the authors found that caspase-3 is activated in RGCs,
where it cleaves APP to produce neurotoxic fragments that
include Ab.19 This suggested a new hypothesis for RGC death in
glaucoma involving chronic Ab neurotoxicity, mimicking AD at
the molecular level.11 A study published by Guo et al in 200714
provided evidence that targeting Ab and blocking its effects
with combination therapy may represent an effective treatment
strategy in glaucoma. Further evidence of a link between AD
and glaucoma has emerged from studies showing that patients
with AD exhibit optic nerve degeneration and loss of RGCs.20 21
In addition, other studies found a significantly increased
occurrence rate of glaucoma among patients with AD.8 22 In a
study based in nursing homes in Germany, the prevalences of
glaucoma (as defined by characteristic optic nerve or visual field
changes) were reported to be 25.9% in patients with AD and
5.2% in controls.22 In addition, the occurrence rate of ocular
hypertension with normal visual fields and normal optic nerve
heads in patients with AD was 0% compared with a prevalence
of about 7% in the control subjects.22 The authors assumed that
the optic nerve was less resistant to elevated IOP levels in AD
patients.22 In another study, Tamura et al8 found that the
prevalence of OAG in Japanese patients with AD was 23.8%,
which was significantly higher than that of the control subjects
(9.9%). Furthermore, there was no significant difference
between IOPs in AD patients with OAG and without OAG,
and almost all AD patients with OAG had normal tension.8 The
authors concluded by suggesting that careful attention should
be given to the potential for OAG in AD patients, stressing the
importance of not giving the impression to non-ophthalmic
trained physicians or clinicians that OAG would be manifest
through visual disturbance.8
In spite of intensive research, the clinical and genetic
relationships between AD and glaucoma remain obscure.8 It is
unclear whether the clinical correlation between the two
diseases might be due to shared risk factors or the influence of
one disorder on the other. There are several candidate common
risk factors. For example, Tamura et al8 evaluated the APOE e4
allele as a common risk factor for AD and OAG. The percentage
of AD patients with OAG who carried an APOE e4 allele was
not significantly different than that of AD patients without
OAG.8 Their results suggested that APOE e4 polymorphism may
not be a common risk factor predisposing to both disorders.8
Recently, Helicobacter pylori infection has also been suggested to
be involved in the pathogenesis of both AD and glaucoma.23 To
investigate whether primary open-angle glaucoma (POAG) is
associated with increased risk of developing AD, Kessing et al24
carried out a nationwide case register study comparing the rate
of subsequent AD for patients with POAG (including normal
tension glaucoma) with the rate for patients with primary
angle-closure glaucoma (PACG), cataract and osteoarthritis
(OA) and with the rate for the general population. All patients
included in the study were identified at hospital admission or
outpatient contact during the period from 1977 to 2001 in
Denmark.24 The authors did not confirm the hypothesis that
patients with POAG have increased risk of developing AD.24
Indeed, patients with POAG did not have an increased rate of
subsequent AD compared with patients with PACG, cataract or
OA or when compared with the general population.24
PRESENTATION OF THE HYPOTHESIS
As noted above, we hypothesise that there may be a causal
relationship between AD and glaucoma that may be explained
by decreased CSFP in patients with AD. In a retrospective case–
control study, Berdahl et al25 reported the intriguing new
observation that mean CSFP was 33% lower in subjects with
POAG (9.2 mmHg) than that of non-glaucomatous controls
(13.0 mmHg; p,0.00005). Subjects were considered to have
POAG if they were diagnosed with POAG by a glaucoma
specialist, had characteristic optic nerve changes, and had visual
field loss consistent with glaucoma.25 The criteria did not
include IOP, because POAG occurs across the entire spectrum of
IOP.25 26 The authors noted that their observation supports the
concept that an abnormal high trans-lamina cribrosa pressure
difference (a pressure difference across the lamina cribrosa),
whether the result of elevated IOP, reduced CSFP, or both, plays
an important role in glaucomatous optic nerve damage.25 The
lamina cribrosa forms the bottom of the optic cup in the optic
nerve head (optic disc) and acts as a pressure barrier between
the intraocular pressure space and the retrobulbar CSF pressure
space.10 27 Normally, the IOP ranges from 10 to 21 mmHg,
whereas the CSFP ranges from 5 to 15 mmHg (or 68 to
204 mmH2O).
25 From a mechanical perspective, a similar
posteriorly directed force is caused by either a lower pressure
on the CSF side of the lamina or a higher pressure on the
intraocular side.25 Berdahl et al25 found that IOP, CSFP and the
trans-lamina cribrosa pressure difference all correlated with cup-
to-disc ratio. Multivariate analysis showed that larger cup-to-
disc ratio (an important parameter in the assessment of disc
damage in glaucoma) was associated with lower CSFP.25
Importantly, the observation of Berdahl et al25 may also shed
new light on the link between AD and glaucoma. Silverberg et
al28 reported in 2006 on CSFP in patients with AD. In a clinical
trial of low-flow CSF shunting for AD, AD subjects by National
Institutes of Neurological and Communicative Diseases and
Stroke–Alzheimer’s Disease and Related Disorders Association
criteria were carefully screened to exclude those with normal
pressure hydrocephalus (NPH).28 As a final exclusion prior to
shunt implantation, CSFP was measured supine under general
anaesthesia via the implanted ventricular catheter.28 During the
initial implantation procedure, seven of the 181 subjects (3.9%)
with no clinical or radiographic signs of NPH had an opening
CSFP .200 mmH2O.
28 These subjects were withdrawn from
the remainder of the study, because of probable associated early
NPH.28 For this AD-elevated CSFP group, the mean CSFP was
249 (SD 20) mmH2O.
28 AD patients with elevated CSFP were
significantly younger and significantly less demented on the
Mattis Dementia Rating Scale (MDRS) than those without
elevated CSFP.28 The AD group without elevated CSFP
consisted of 174 subjects (the remaining 96.1%).28 Mean opening
CSFP in this group was 103 (SD 47) mmH2O, which was
statistically significantly lower than in the AD-elevated CSFP
group and a somewhat younger non-demented control group of
subjects with Parkinson’s disease (140 (SD 60) mmH2O).
28 29
The distribution of CSFP in all AD subjects is shown in fig 1.
Remarkably, the frequency histogram of the CSFP distribution
shows a substantial proportion of AD patients with very low
CSFP. Indeed, it could be argued that there are really two
subgroups of AD patients within the group without elevated
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CSFP: those with nearly normal CSFP and those with much
lower CSFP (G. Silverberg, personal communication, 2008). An
unexpected finding of this study was the relatively high
proportion of subjects (.30%) with moderate to severe
dementia as measured by MDRS total scores below 100, despite
inclusion–exclusion criteria designed to capture subjects with
mild to moderate dementia (Mini-Mental State Examination
score between 15 and 24, inclusive).28 30 Cerebral atrophy
associated with moderate to severe AD could be assumed to
be the cause of the lower CSFP (G. Silverberg, personal
communication, 2008). However, this has not been specifically
investigated in this study (G. Silverberg, personal communica-
tion, 2008). Given the observation that a substantial proportion
of AD patients has very low CSFP,28 and given that a reduction
in CSFP may produce an abnormal high trans-lamina cribrosa
pressure difference leading to glaucomatous damage,25 26 we
hypothesise that such a high pressure difference may explain
why patients with AD have a greater risk for developing
glaucoma. This obviously needs to be confirmed by future
research. In addition, it should be stressed that it may be
possible to hypothesise other factors that also might explain the
link between AD and glaucoma.
TESTING THE HYPOTHESIS
To assess whether decreased CSFP is associated with OAG in
patients with AD, CSFP could be compared between AD
patients with OAG, AD patients without OAG, and appropriate
controls. A significantly lower CSFP in AD patients with OAG
compared with that in AD patients without OAG would
support our hypothesis.
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Figure 1 Frequency histogram showing the distribution of
cerebrospinal fluid pressure (CSFP) in all subjects with Alzeimer’s
disease (AD). Reproduced with permission from Silverberg et al.28 NPH,
normal pressure hydrocephalus.
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